Unicycive Therapeutics (Nasdaq: UNCY) announced resubmission of its 505(b)(2) New Drug Application (NDA) to the FDA for oxylanthanum carbonate (OLC), a phosphate binder for treating hyperphosphatemia in patients with chronic kidney disease on dialysis. A new PDUFA target date is expected in 1H 2026, within 30 days of the resubmission. Unicycive Therapeutics is a B2i Digital Featured Company. View their comprehensive profile at b2idigital.com/unicycive. The resubmission reflects progress by the o

1.9K views · 12 reactions | Ever wonder how new drugs come to be? Learn about the drug development process and how the FDA ensures new treatments are safe and effective for the people who need them: https://www.fda.gov/patients/learn-about-drug-and-device-approvals/drug-development-process | U.S. Food and Drug Administration | Facebook